GLP-1s have gone so far as to disrupt the food, clothing, and, of course, weight-loss industries. Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy ...

It’s going to be an experiment to go off of it.” As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, ...

Dr. Jonathan Kaplan, a board-certified plastic surgeon from San Francisco, has amassed 1.6 million views on TikTok (@ realdrbae) with his warning: "Once you stop Ozempic, you will regain the weight." ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly And Co (NYSE:LLY) experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick ...

City employees in NYC had insurance coverage for GLP-1 drugs like Wegovy and Zepbound for less than a year before learning it ...

One interesting distinction in the weight loss drug landscape is that of injectable drugs versus oral drugs. Lilly and Novo currently deliver their drugs Zepbound and Wevogy, via self-injections.

Weight-loss drugs like Wegovy and Zepbound are transforming the health of millions of people—and a new study hints that even more could benefit from the drugs’ other effects on the body.

In a court filing earlier this month, the FDA agreed to reconsider a decision last month to bar drug compounders from selling their versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

Eli Lilly sues medical spas and vendors for selling unauthorized tirzepatide, the active ingredient in its weight-loss drug, Zepbound. The lawsuits aim to stop the sale of unapproved tirzepatide ...